Kugler Vision Participates in FDA Approval of Corneal Crosslinking for Treatment of Keratoconus

Kugler Vision (www.lasikomaha.com) in Omaha, NE is a leader in ophthalmology and refractive surgery and has been a principal investigator for the clinical trials conducted for corneal crosslinking.

Corneal crosslinking is therapeutic treatment for Keratoconus, a sight-threatening eye condition that affects approximately one in every 2,000 Americans or approximately 170,000 people in the United States. This innovative treatment aims to halt the progress of keratoconus by strengthening chemical bonds in the cornea, which can avert the need for a corneal transplant. The US Food and Drug Administration (FDA) approved a riboflavin ophthalmic solution (Photrexa, Avedro, Waltham, MA) that treats progressive keratoconus with corneal collagen crosslinking in April 2015.

The FDA has officially determined that corneal crosslinking for keratoconus is safe and effective based on three 12-month clinical trials conducted in the United States. Kugler Vision was a principal investigator in one of the three 12-month clinical trials, and on November 7, 2012, Kugler Vision became the first institution in Nebraska to perform the corneal crosslinking procedure. After reviewing the data from the study sites, the FDA recently approved the technology in April of 2016.

Kugler Vision’s mission is to remain on the forefront of scientific advancements that improve its patients’ lives, and is excited to offer this new vision technology. Call (402) 558-2211 or visit www.lasikomaha.com for more information about Kugler Vision.